Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Sanofi/Regeneron Get Reprieve: Praluent Can Stay On Market For Now

09 Feb 2017

• By Brenda Sandburg

court house

Related Content

PCSK9 Patent Fight: Amgen Opposes Doctor Efforts To Keep Praluent On Market

27 Jan 2017

‘Between A Rock And A Hard Place,’ Court Issues Injunction To Halt Praluent Sales

06 Jan 2017

Praluent Fate Uncertain After Amgen Wins PCSK9 Patent Battle

17 Mar 2016

Amgen’s Repatha Passes CVOT Test, But Contribution To 2017 Sales Growth Unclear

03 Feb 2017

Related Companies

Sanofi

Regeneron Pharmaceuticals, Inc.

Amgen, Inc.

Additional Topics

Intellectual Property Legal Issues Policy BioPharmaceutical

More from Legal & IP

More from Pink Sheet

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window

Copyright © 2025 Pharma Intelligence UK Limited (Citeline), a Norstella company Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered.